Shopping Cart 0
Cart Subtotal
USD 0

Horizon Pharma Plc (HZNP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Horizon Pharma plc (Horizon Pharma) is a pharmaceutical company which develops and commercializes medical products for the treatment of pain, arthritis and inflammatory diseases. It markets medicines through its orphan, primary care and rheumatology business units. The company's marketed products include Actimmune, Buphenyl, Duexis, Krystexxa, Migergot, Pennsaid 2%, Procysbi, Quinsair, Ravicti, Rayos and Vimovo. Horizon Pharma provides products and services to patients and healthcare professionals in the US. The company operates through offices in Illinois, California, Switzerland, the Netherlands and Germany. Horizon Pharma is headquartered in Dublin, Ireland.

Horizon Pharma Plc (HZNP)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 6

Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Horizon Pharma Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deal Details 15

Asset Purchase 15

Horizon Pharma Acquires Worldwide Rights to Interferon Gamma-1b from Boehringer Ingelheim for USD28.2 Million 15

Horizon Pharma Acquires US Rights to Pennsaid 2% from Nuvo Research for USD45 Million 16

Hyperion Therapeutics Completes Acquisition Of Rights To Buphenyl And Ammonul From Ucyclyd Pharma For USD 51 Million 18

Vidara Therapeutics International Acquires Actimmune From InterMune For USD 55 Million 20

Hyperion Therapeutics Acquires Rights Of Ravicti From Ucyclyd Pharma 22

Venture Financing 23

River Vision Development Raises USD5 Million in Financing Round 23

River Vision Development Raises USD5.3 Million in Financing Round 24

River Vision Development Raises USD6 Million in Financing Round 25

River Vision Development Raises USD 17 Million In Series A Financing 26

Hyperion Therapeutics Raises USD 15 Million In Series D-II Financing 27

Private Equity 28

Vidara Therapeutics Raises Funds Through Private Equity Financing 28

Partnerships 29

Horizon Pharma Enters into Agreement with XL-protein 29

Swedish Orphan Biovitrum Enters into Distribution Agreement with Horizon Pharma for Ravicti 30

Swedish Orphan Biovitrum Enters into Distribution Agreement with Horizon Pharma for Ammonaps 31

Clinigen Group Partners with Horizon Pharma 32

Horizon Pharma Enters into Agreement with Alliance for Lupus Research 33

Horizon Pharma And Mundipharma Amend Distribution Agreement For Lodotra 34

Swedish Orphan Biovitrum Enters Into Distribution Agreement With Hyperion Therapeutics 36

Mallinckrodt Enters Into Co-Promotion Agreement With Horizon Pharma For Duexis 37

Horizon Pharma Amends Co-Marketing Agreement With Mundipharma International For LODOTRA 38

Licensing Agreements 40

Horizon Pharma Enters into Licensing Agreement with MedImmune for MEDI4945 40

Horizon Pharma Enters into Licensing Agreement for Interferon Gamma-1b 41

Grunenthal Enters Into Licensing Agreement With Horizon Pharma For Duexis 42

Equity Offering 43

Horizon Pharma Raises USD499 million in Public Offering of Shares 43

Hyperion Therapeutics Files Registration Statement For Public Offering Of Securities For USD 150 Million 45

Hyperion Therapeutics Completes Public Offering Of Common Stock For USD 69 Million 46

Horizon Pharma Completes Public Offering Of Units For USD 86 Million 47

Hyperion Therapeutics Completes IPO For USD 57.5 Million 48

Horizon Pharma Completes Private Placement Of Units For USD 51 Million 49

Debt Offering 50

Horizon Pharma Raises USD300 Million in Private Placement of 8.75% Notes Due 2024 50

Horizon Pharma Raises USD475 Million in Private Placement of 6.625% Notes Due 2023 51

Horizon Pharma Raises USD400 Million in Private Placement of 2.5% Senior Notes Due 2022 53

Horizon Pharma Completes Private Placement Of Notes Due 2018 For USD 150 Million 55

Asset Transactions 56

Clinigen Acquires Imukin from Horizon Pharma 56

Horizon Pharma May Sell its Primary Care Drugs Business 57

Horizon Pharma Sells PROCYSBI and QUINSAIR to Chiesi Farmaceutici 58

Acquisition 59

Horizon Pharma Acquires River Vision Development 59

Horizon Pharma Acquires Raptor Pharma in Tender Offer 60

Horizon Pharma May Sell Equity Stake in The Company 62

Horizon Pharma Acquires Crealta for USD510 Million 63

Horizon Pharma Acquires Hyperion Therapeutics for USD1.1 Billion 64

Horizon Pharma Acquires Vidara Therapeutics International for USD660 Million in Reverse Acquisition 66

Horizon Pharma Plc-Key Competitors 68

Horizon Pharma Plc-Key Employees 69

Horizon Pharma Plc-Locations And Subsidiaries 70

Head Office 70

Other Locations & Subsidiaries 70

Recent Developments 71

Financial Announcements 71

Nov 07, 2018: Horizon pharma reports third-quarter net sales growth of 20 percent driven by Orphan and Rheumatology net sales growth of 25 percent 71

Aug 08, 2018: Horizon pharma reports record quarterly net sales for orphan and rheumatology segment; increases full-year 2018 adjusted EBITDA guidance; implements new company operating structure to enhance focus on rare diseases 73

May 09, 2018: Horizon Pharma Reports Strong First-Quarter 2018 Orphan and Rheumatology Net Sales Growth 76

Feb 28, 2018: Horizon Pharma Announces Fourth-Quarter and Full-Year 2017 Results 79

Nov 06, 2017: Horizon Pharma Announces Third-Quarter and Year-to-Date 2017 Results 83

Aug 07, 2017: Horizon Pharma Announces Second-Quarter and Year-to-Date 2017 Results and Increases Full-Year 2017 Net Sales and Adjusted EBITDA Guidance 86

May 08, 2017: Horizon Pharma Announces First-Quarter 2017 Results and Revises Full-Year 2017 Net Sales and Adjusted EBITDA Guidance 90

Corporate Communications 93

Nov 30, 2017: Horizon Pharma Names Shao-Lee Lin, M.D., Ph.D. Executive Vice President, Research and Development and Chief Scientific Officer 93

Sep 11, 2017: Horizon Pharma Names Irina Konstantinovsky Executive Vice President, Chief Human Resources Officer 94

Aug 03, 2017: Horizon Pharma Appoints Pascale Witz and James Shannon, M.D. to Board of Directors 95

Other Significant Developments 96

Sep 27, 2018: The north american pediatric renal trials and collaborative studies and Horizon Pharma announce new long-term cystinosis registry 96

Jun 04, 2018: Horizon Pharma and the National Organization for Rare Disorders (NORD) Illustrate 35 years of Progress in Rare Disease at the Biotechnology Innovation Organization (BIO) International Convention 97

Jan 08, 2018: Horizon Pharma Increases Peak Net Sales Guidance for Key Growth Drivers and Announces Rheumatology and Orphan Pipeline Developments 98

Mar 16, 2017: Horizon Pharma Announces "UCD in Common" for the Urea Cycle Disorder Community 101

Appendix 102

Methodology 102

About GlobalData 102

Contact Us 102

Disclaimer 102


List Of Figure

List of Figures

Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10


List Of Table

List of Tables

Horizon Pharma Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Horizon Pharma Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Horizon Pharma Plc, Deals By Therapy Area, 2012 to YTD 2018 10

Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Horizon Pharma Acquires Worldwide Rights to Interferon Gamma-1b from Boehringer Ingelheim for USD28.2 Million 15

Horizon Pharma Acquires US Rights to Pennsaid 2% from Nuvo Research for USD45 Million 16

Hyperion Therapeutics Completes Acquisition Of Rights To Buphenyl And Ammonul From Ucyclyd Pharma For USD 51 Million 18

Vidara Therapeutics International Acquires Actimmune From InterMune For USD 55 Million 20

Hyperion Therapeutics Acquires Rights Of Ravicti From Ucyclyd Pharma 22

River Vision Development Raises USD5 Million in Financing Round 23

River Vision Development Raises USD5.3 Million in Financing Round 24

River Vision Development Raises USD6 Million in Financing Round 25

River Vision Development Raises USD 17 Million In Series A Financing 26

Hyperion Therapeutics Raises USD 15 Million In Series D-II Financing 27

Vidara Therapeutics Raises Funds Through Private Equity Financing 28

Horizon Pharma Enters into Agreement with XL-protein 29

Swedish Orphan Biovitrum Enters into Distribution Agreement with Horizon Pharma for Ravicti 30

Swedish Orphan Biovitrum Enters into Distribution Agreement with Horizon Pharma for Ammonaps 31

Clinigen Group Partners with Horizon Pharma 32

Horizon Pharma Enters into Agreement with Alliance for Lupus Research 33

Horizon Pharma And Mundipharma Amend Distribution Agreement For Lodotra 34

Swedish Orphan Biovitrum Enters Into Distribution Agreement With Hyperion Therapeutics 36

Mallinckrodt Enters Into Co-Promotion Agreement With Horizon Pharma For Duexis 37

Horizon Pharma Amends Co-Marketing Agreement With Mundipharma International For LODOTRA 38

Horizon Pharma Enters into Licensing Agreement with MedImmune for MEDI4945 40

Horizon Pharma Enters into Licensing Agreement for Interferon Gamma-1b 41

Grunenthal Enters Into Licensing Agreement With Horizon Pharma For Duexis 42

Horizon Pharma Raises USD499 million in Public Offering of Shares 43

Hyperion Therapeutics Files Registration Statement For Public Offering Of Securities For USD 150 Million 45

Hyperion Therapeutics Completes Public Offering Of Common Stock For USD 69 Million 46

Horizon Pharma Completes Public Offering Of Units For USD 86 Million 47

Hyperion Therapeutics Completes IPO For USD 57.5 Million 48

Horizon Pharma Completes Private Placement Of Units For USD 51 Million 49

Horizon Pharma Raises USD300 Million in Private Placement of 8.75% Notes Due 2024 50

Horizon Pharma Raises USD475 Million in Private Placement of 6.625% Notes Due 2023 51

Horizon Pharma Raises USD400 Million in Private Placement of 2.5% Senior Notes Due 2022 53

Horizon Pharma Completes Private Placement Of Notes Due 2018 For USD 150 Million 55

Clinigen Acquires Imukin from Horizon Pharma 56

Horizon Pharma May Sell its Primary Care Drugs Business 57

Horizon Pharma Sells PROCYSBI and QUINSAIR to Chiesi Farmaceutici 58

Horizon Pharma Acquires River Vision Development 59

Horizon Pharma Acquires Raptor Pharma in Tender Offer 60

Horizon Pharma May Sell Equity Stake in The Company 62

Horizon Pharma Acquires Crealta for USD510 Million 63

Horizon Pharma Acquires Hyperion Therapeutics for USD1.1 Billion 64

Horizon Pharma Acquires Vidara Therapeutics International for USD660 Million in Reverse Acquisition 66

Horizon Pharma Plc, Key Competitors 68

Horizon Pharma Plc, Key Employees 69

Horizon Pharma Plc, Subsidiaries 70

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Horizon Pharma Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Horizon Pharma plc (Horizon Pharma) is a pharmaceutical company which develops and commercializes medical products for the treatment of pain, arthritis and inflammatory diseases. It markets medicines through its orphan, primary care and rheumatology business units. The company's marketed products include Actimmune, Buphenyl, Duexis, Krystexxa, Migergot, Pennsaid 2%, Procysbi, Quinsair, Ravicti, Rayos and Vimovo. Horizon Pharma provides products and services to patients and healthcare professionals in the US. The company operates through offices in Illinois, California, Switzerland, the Netherlands and Germany. Horizon Pharma is headquartered in Dublin, Ireland.

Horizon Pharma Plc (HZNP)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 6

Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Horizon Pharma Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deal Details 15

Asset Purchase 15

Horizon Pharma Acquires Worldwide Rights to Interferon Gamma-1b from Boehringer Ingelheim for USD28.2 Million 15

Horizon Pharma Acquires US Rights to Pennsaid 2% from Nuvo Research for USD45 Million 16

Hyperion Therapeutics Completes Acquisition Of Rights To Buphenyl And Ammonul From Ucyclyd Pharma For USD 51 Million 18

Vidara Therapeutics International Acquires Actimmune From InterMune For USD 55 Million 20

Hyperion Therapeutics Acquires Rights Of Ravicti From Ucyclyd Pharma 22

Venture Financing 23

River Vision Development Raises USD5 Million in Financing Round 23

River Vision Development Raises USD5.3 Million in Financing Round 24

River Vision Development Raises USD6 Million in Financing Round 25

River Vision Development Raises USD 17 Million In Series A Financing 26

Hyperion Therapeutics Raises USD 15 Million In Series D-II Financing 27

Private Equity 28

Vidara Therapeutics Raises Funds Through Private Equity Financing 28

Partnerships 29

Horizon Pharma Enters into Agreement with XL-protein 29

Swedish Orphan Biovitrum Enters into Distribution Agreement with Horizon Pharma for Ravicti 30

Swedish Orphan Biovitrum Enters into Distribution Agreement with Horizon Pharma for Ammonaps 31

Clinigen Group Partners with Horizon Pharma 32

Horizon Pharma Enters into Agreement with Alliance for Lupus Research 33

Horizon Pharma And Mundipharma Amend Distribution Agreement For Lodotra 34

Swedish Orphan Biovitrum Enters Into Distribution Agreement With Hyperion Therapeutics 36

Mallinckrodt Enters Into Co-Promotion Agreement With Horizon Pharma For Duexis 37

Horizon Pharma Amends Co-Marketing Agreement With Mundipharma International For LODOTRA 38

Licensing Agreements 40

Horizon Pharma Enters into Licensing Agreement with MedImmune for MEDI4945 40

Horizon Pharma Enters into Licensing Agreement for Interferon Gamma-1b 41

Grunenthal Enters Into Licensing Agreement With Horizon Pharma For Duexis 42

Equity Offering 43

Horizon Pharma Raises USD499 million in Public Offering of Shares 43

Hyperion Therapeutics Files Registration Statement For Public Offering Of Securities For USD 150 Million 45

Hyperion Therapeutics Completes Public Offering Of Common Stock For USD 69 Million 46

Horizon Pharma Completes Public Offering Of Units For USD 86 Million 47

Hyperion Therapeutics Completes IPO For USD 57.5 Million 48

Horizon Pharma Completes Private Placement Of Units For USD 51 Million 49

Debt Offering 50

Horizon Pharma Raises USD300 Million in Private Placement of 8.75% Notes Due 2024 50

Horizon Pharma Raises USD475 Million in Private Placement of 6.625% Notes Due 2023 51

Horizon Pharma Raises USD400 Million in Private Placement of 2.5% Senior Notes Due 2022 53

Horizon Pharma Completes Private Placement Of Notes Due 2018 For USD 150 Million 55

Asset Transactions 56

Clinigen Acquires Imukin from Horizon Pharma 56

Horizon Pharma May Sell its Primary Care Drugs Business 57

Horizon Pharma Sells PROCYSBI and QUINSAIR to Chiesi Farmaceutici 58

Acquisition 59

Horizon Pharma Acquires River Vision Development 59

Horizon Pharma Acquires Raptor Pharma in Tender Offer 60

Horizon Pharma May Sell Equity Stake in The Company 62

Horizon Pharma Acquires Crealta for USD510 Million 63

Horizon Pharma Acquires Hyperion Therapeutics for USD1.1 Billion 64

Horizon Pharma Acquires Vidara Therapeutics International for USD660 Million in Reverse Acquisition 66

Horizon Pharma Plc-Key Competitors 68

Horizon Pharma Plc-Key Employees 69

Horizon Pharma Plc-Locations And Subsidiaries 70

Head Office 70

Other Locations & Subsidiaries 70

Recent Developments 71

Financial Announcements 71

Nov 07, 2018: Horizon pharma reports third-quarter net sales growth of 20 percent driven by Orphan and Rheumatology net sales growth of 25 percent 71

Aug 08, 2018: Horizon pharma reports record quarterly net sales for orphan and rheumatology segment; increases full-year 2018 adjusted EBITDA guidance; implements new company operating structure to enhance focus on rare diseases 73

May 09, 2018: Horizon Pharma Reports Strong First-Quarter 2018 Orphan and Rheumatology Net Sales Growth 76

Feb 28, 2018: Horizon Pharma Announces Fourth-Quarter and Full-Year 2017 Results 79

Nov 06, 2017: Horizon Pharma Announces Third-Quarter and Year-to-Date 2017 Results 83

Aug 07, 2017: Horizon Pharma Announces Second-Quarter and Year-to-Date 2017 Results and Increases Full-Year 2017 Net Sales and Adjusted EBITDA Guidance 86

May 08, 2017: Horizon Pharma Announces First-Quarter 2017 Results and Revises Full-Year 2017 Net Sales and Adjusted EBITDA Guidance 90

Corporate Communications 93

Nov 30, 2017: Horizon Pharma Names Shao-Lee Lin, M.D., Ph.D. Executive Vice President, Research and Development and Chief Scientific Officer 93

Sep 11, 2017: Horizon Pharma Names Irina Konstantinovsky Executive Vice President, Chief Human Resources Officer 94

Aug 03, 2017: Horizon Pharma Appoints Pascale Witz and James Shannon, M.D. to Board of Directors 95

Other Significant Developments 96

Sep 27, 2018: The north american pediatric renal trials and collaborative studies and Horizon Pharma announce new long-term cystinosis registry 96

Jun 04, 2018: Horizon Pharma and the National Organization for Rare Disorders (NORD) Illustrate 35 years of Progress in Rare Disease at the Biotechnology Innovation Organization (BIO) International Convention 97

Jan 08, 2018: Horizon Pharma Increases Peak Net Sales Guidance for Key Growth Drivers and Announces Rheumatology and Orphan Pipeline Developments 98

Mar 16, 2017: Horizon Pharma Announces "UCD in Common" for the Urea Cycle Disorder Community 101

Appendix 102

Methodology 102

About GlobalData 102

Contact Us 102

Disclaimer 102


List Of Figure

List of Figures

Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10


List Of Table

List of Tables

Horizon Pharma Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Horizon Pharma Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Horizon Pharma Plc, Deals By Therapy Area, 2012 to YTD 2018 10

Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Horizon Pharma Acquires Worldwide Rights to Interferon Gamma-1b from Boehringer Ingelheim for USD28.2 Million 15

Horizon Pharma Acquires US Rights to Pennsaid 2% from Nuvo Research for USD45 Million 16

Hyperion Therapeutics Completes Acquisition Of Rights To Buphenyl And Ammonul From Ucyclyd Pharma For USD 51 Million 18

Vidara Therapeutics International Acquires Actimmune From InterMune For USD 55 Million 20

Hyperion Therapeutics Acquires Rights Of Ravicti From Ucyclyd Pharma 22

River Vision Development Raises USD5 Million in Financing Round 23

River Vision Development Raises USD5.3 Million in Financing Round 24

River Vision Development Raises USD6 Million in Financing Round 25

River Vision Development Raises USD 17 Million In Series A Financing 26

Hyperion Therapeutics Raises USD 15 Million In Series D-II Financing 27

Vidara Therapeutics Raises Funds Through Private Equity Financing 28

Horizon Pharma Enters into Agreement with XL-protein 29

Swedish Orphan Biovitrum Enters into Distribution Agreement with Horizon Pharma for Ravicti 30

Swedish Orphan Biovitrum Enters into Distribution Agreement with Horizon Pharma for Ammonaps 31

Clinigen Group Partners with Horizon Pharma 32

Horizon Pharma Enters into Agreement with Alliance for Lupus Research 33

Horizon Pharma And Mundipharma Amend Distribution Agreement For Lodotra 34

Swedish Orphan Biovitrum Enters Into Distribution Agreement With Hyperion Therapeutics 36

Mallinckrodt Enters Into Co-Promotion Agreement With Horizon Pharma For Duexis 37

Horizon Pharma Amends Co-Marketing Agreement With Mundipharma International For LODOTRA 38

Horizon Pharma Enters into Licensing Agreement with MedImmune for MEDI4945 40

Horizon Pharma Enters into Licensing Agreement for Interferon Gamma-1b 41

Grunenthal Enters Into Licensing Agreement With Horizon Pharma For Duexis 42

Horizon Pharma Raises USD499 million in Public Offering of Shares 43

Hyperion Therapeutics Files Registration Statement For Public Offering Of Securities For USD 150 Million 45

Hyperion Therapeutics Completes Public Offering Of Common Stock For USD 69 Million 46

Horizon Pharma Completes Public Offering Of Units For USD 86 Million 47

Hyperion Therapeutics Completes IPO For USD 57.5 Million 48

Horizon Pharma Completes Private Placement Of Units For USD 51 Million 49

Horizon Pharma Raises USD300 Million in Private Placement of 8.75% Notes Due 2024 50

Horizon Pharma Raises USD475 Million in Private Placement of 6.625% Notes Due 2023 51

Horizon Pharma Raises USD400 Million in Private Placement of 2.5% Senior Notes Due 2022 53

Horizon Pharma Completes Private Placement Of Notes Due 2018 For USD 150 Million 55

Clinigen Acquires Imukin from Horizon Pharma 56

Horizon Pharma May Sell its Primary Care Drugs Business 57

Horizon Pharma Sells PROCYSBI and QUINSAIR to Chiesi Farmaceutici 58

Horizon Pharma Acquires River Vision Development 59

Horizon Pharma Acquires Raptor Pharma in Tender Offer 60

Horizon Pharma May Sell Equity Stake in The Company 62

Horizon Pharma Acquires Crealta for USD510 Million 63

Horizon Pharma Acquires Hyperion Therapeutics for USD1.1 Billion 64

Horizon Pharma Acquires Vidara Therapeutics International for USD660 Million in Reverse Acquisition 66

Horizon Pharma Plc, Key Competitors 68

Horizon Pharma Plc, Key Employees 69

Horizon Pharma Plc, Subsidiaries 70

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Horizon Pharma Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.